Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Organic nanoparticle-based (ONP) gene therapy is a potential strategy to cure human cancer. However, there are still many practical barriers before the promising results from in vitro and preclinical studies can be translated to clinical success. We discuss the reasons behind the hesitant uptake by the clinic.

Original publication

DOI

10.1016/j.tibtech.2017.07.009

Type

Journal article

Journal

Trends Biotechnol

Publication Date

12/2017

Volume

35

Pages

1124 - 1125

Keywords

clinical trials, gene therapy, limitations, organic nanoparticle